3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma
3
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Vomiting
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Nausea and Vomiting
1
Philadelphia Chromosome
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Nausea
1
Metastatic Neuroendocrine Prostate Cancer
1
Medulloblastoma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Ependymoma
1
Colorectal Neoplasms
1
Chondrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Solid Tumors
1
Interventions
Docetaxel
277
Prednisone
237
enzalutamide
177
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
154
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
79
abiraterone
77
gallium 68 PSMA-11
74
Specimen Handling
67
darolutamide
58
Gonadotropin-Releasing Hormone
58
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
50
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
Antiemetics
×
Clear all
NCT03050866
2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2
Unknown
140 enrolled